AI cancer treatment startup Nucleai raises $6.5 million in series A round
Tel Aviv-based cancer detection startup Nucleai has raised $6.5 million in a series A funding round led by Debiopharm Group, with participation from existing investors, such as Grove Ventures, a top Israeli venture capital firm. Nucleai’s software utilizes computer vision and machine learning algorithms to predict the progression of cancerous tumors and the patient’s immune system response, aiding in personalized treatment decisions. The funding will be used for research and development as well as expanding commercial partnerships with pharmaceutical and biotech companies. Nucleai aims to enhance clinical research and improve diagnostic accuracy with its AI-powered platform, which has the potential to revolutionize cancer treatment.
>> Click here to read the full article originally published in CTech: https://www.calcalistech.com/ctech/articles/0,7340,L-3838379,00.html